Murine Models of Systemic Lupus Erythematosus

10.1038/gene.2009.39

10.1007/s00281-006-0030-7

10.1038/nrrheum.2010.63

10.1016/S0065-2776(08)60342-9

10.1084/jem.147.6.1568

Rudofsky U. H., 1993, Differences in expression of lupus nephritis in New Zealand Mixed H-2(z) homozygous inbred strains of mice derived from New Zealand Black and New Zealand White mice: origins and initial characterization, Laboratory Investigation, 68, 419

10.1016/1074-7613(94)90100-7

10.1006/clim.2001.5079

10.1016/S1074-7613(00)80088-6

10.4049/jimmunol.159.1.454

10.1172/JCI728

10.4049/jimmunol.162.11.6492

10.4049/jimmunol.158.12.6019

10.4049/jimmunol.162.4.2415

10.4049/jimmunol.169.7.4025

10.4049/jimmunol.169.5.2694

10.1084/jem.20031519

10.1073/pnas.97.12.6670

10.1038/sj.gene.6364423

10.1177/0961203309104020

10.1016/S1074-7613(01)00228-X

10.4049/jimmunol.175.2.1080

10.1073/pnas.0609101104

10.1038/gene.2009.27

10.1016/j.immuni.2004.10.009

10.1126/science.1125893

10.1038/sj.gene.6364453

10.1038/ng.205

10.1172/JCI23049

10.1172/JCI36728

10.1084/jem.148.5.1198

10.1084/jem.176.6.1645

10.1016/j.immuni.2009.01.001

10.1084/jem.178.2.723

10.4049/jimmunol.154.2.936

10.1016/0092-8674(94)90375-1

10.1016/1074-7613(94)90106-6

10.1111/j.1365-2141.2009.07991.x

10.1006/cimm.1994.1057

10.1084/jem.180.4.1295

10.1084/jem.20032196

10.4049/jimmunol.133.1.227

10.1016/j.immuni.2007.03.016

10.1016/0090-1229(85)90153-9

10.1172/JCI1817

10.4049/jimmunol.178.12.8195

10.1016/j.immuni.2007.11.023

10.1084/jem.148.5.1198

10.1007/s002510050632

10.1002/art.1780221105

10.4049/jimmunol.125.5.1959

10.4049/jimmunol.134.6.3849

10.1002/eji.1830191124

10.1126/science.1124978

10.1073/pnas.0603912103

10.1016/j.coi.2007.10.004

10.1038/416603a

10.1084/jem.20050630

10.1016/j.immuni.2007.09.009

10.1002/eji.200838138

10.4049/jimmunol.181.2.1556

10.1073/pnas.1001337107

10.1002/eji.1830180612

10.1002/eji.1830220202

10.4049/jimmunol.161.6.2753

10.1002/1529-0131(200002)43:2<349::AID-ANR14>3.0.CO;2-M

10.4049/jimmunol.173.7.4277

10.1038/nrrheum.2010.46

10.1084/jem.155.2.345

10.1016/j.autrev.2010.07.012

10.1002/(SICI)1521-4141(199812)28:12<4257::AID-IMMU4257>3.0.CO;2-H

10.1128/JVI.73.10.8227-8234.1999

10.1016/j.jaut.2010.06.001

10.1084/jem.180.6.2341

10.1073/pnas.92.24.10934

10.1046/j.1365-2249.2000.01276.x

10.1016/j.clim.2006.09.009

10.1084/jem.188.5.985

10.1002/art.10441

10.1046/j.1523-1755.2003.00178.x

10.1046/j.1523-1755.2001.00045.x

10.1016/j.coi.2006.09.014

10.1002/art.23023

10.1186/ar2771

10.1177/0961203308090020

10.4049/jimmunol.180.7.5101

10.2353/ajpath.2009.090328

10.1084/jem.20080462

10.1002/art.23407

10.1084/jem.20050914

10.1093/rheumatology/kem117

10.1191/0961203305lu2107cr

10.1002/anr.1780320812

10.4049/jimmunol.127.4.1591

10.1093/rheumatology/36.10.1129

10.1016/j.it.2010.02.001

10.4049/jimmunol.178.1.95

10.4049/jimmunol.171.11.5795

10.4049/jimmunol.181.1.47

10.4049/jimmunol.153.9.4040

10.4049/jimmunol.168.8.3786

10.4049/jimmunol.167.12.6821

10.4049/jimmunol.178.6.3962

10.1016/0090-1229(90)90040-W

10.1681/ASN.V4158

10.1002/art.27221

10.1046/j.1365-2249.1998.00612.x

10.1111/j.1365-2567.2006.02433.x

10.4049/jimmunol.159.6.2658

10.1002/1529-0131(200008)43:8<1790::AID-ANR15>3.0.CO;2-2

10.1084/jem.179.1.305

10.4049/jimmunol.169.4.2148

10.1038/labinvest.3700468

10.1016/0090-1229(89)90157-8

10.1093/rheumatology/kep270

10.1073/pnas.0900615106

Wallace D. J., 2007, MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematous, Arthritis & Rheumatism, 56, S526

McBride J. M., 2009, Dose-dependent modulation of interferon regulated genes with administration of single and repeat doses of Rontalizumab in a phase I, placebo controlled, double blind, dose escalation study in SLE, Arthritis & Rheumatism, 60, S775

10.1681/ASN.2004111014

10.1172/JCI10167

10.1084/jem.166.3.798

10.1172/JCI42856

10.4049/jimmunol.178.6.3822

10.1073/pnas.2336094100

10.1002/art.27368

Petri M. F., 2009, Four-year experience of belimumab, a BlyS-specific inhibitor, in systemic lupus erythematosus (SLE) patients, Arthritis & Rheumatism, 60

GlaxoSmithKline press release GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of benlysta in systemic lupus erythematosus 2009 http://us.gsk.com/html/media-news/pressreleases/2009/2009_pressrelease_10121.htm.

10.1038/nrrheum.2010.117

10.1084/jem.20100086

10.1038/35010115

10.4049/jimmunol.173.5.3524

10.1002/art.20290

10.4049/jimmunol.179.5.3351

10.1002/art.27233

10.1038/nrrheum.2010.68

US National Library of Medicine A study to evaluate ocrelizumab in patients with nephritis due to systemic lupus erythematosus (BeLONG) 2010 http://clinicaltrials.gov/ct2/show/NCT00626197.

10.4049/jimmunol.0902391

10.1186/ar1942

UCB press release UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLe) 2009 http://www.ucb.com/media-room/newsdetail/?det=1337304.

10.4049/jimmunol.181.5.2961

10.1038/nm1763

10.1126/science.7520604

10.4049/jimmunol.159.7.3104

US National Library of Medicine Abatacept and cyclophosphamide combination therapy for lupus nephritis (ACCeSS) 2010 http://clinicaltrials.gov/ct2/show/NCT00774852.

10.1172/JCI9244

10.4049/jimmunol.0804349

10.4049/jimmunol.181.9.6038

10.4049/jimmunol.182.3.1421

10.1126/science.1105160

10.1002/eji.200737815

10.4049/jimmunol.0903401

10.1002/art.23428

10.1002/art.27452

10.1038/nm1291

10.1093/ndt/gfn216

10.1002/art.22085

10.4049/jimmunol.0803052

10.4049/jimmunol.177.3.1451

10.1371/journal.pone.0006031

10.1177/0961203310373782

10.1136/ard.2009.123463

ChangJ. HungS. WuH.et al. Therapeutic effects of umbilical cord blood-derived mesenchymal stem cell transplantation in experimental lupus nephritis Cell Transplantation. In press.

10.1002/art.27560

10.1002/art.1780210403

Sturgess A. D., 1984, Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus, Journal of Clinical and Laboratory Immunology, 13, 11

10.1136/ard.62.4.341

10.1046/j.1365-3083.2000.00789.x

Abdou N. I., 2008, Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial, Journal of Rheumatology, 35, 797

10.3899/jrheum.090911

10.1016/j.clim.2009.01.013

10.1172/JCI108729

Moszkorzová L., 2002, Hyperprolactinaemia in patients with systemic lupus erythematous, Clinical and Experimental Rheumatology, 20, 807

10.4049/jimmunol.125.2.871

10.4049/jimmunol.175.8.5516

10.1002/immu.200310002

10.1371/journal.pone.0005273

10.1002/art.24027

10.4049/jimmunol.162.10.5775

10.1002/1529-0131(200102)44:2<432::AID-ANR62>3.0.CO;2-S

10.4049/jimmunol.175.11.7728

10.4049/jimmunol.180.4.2069

10.1016/j.autrev.2010.07.004

10.1172/JCI200316153

10.4049/jimmunol.0903153

10.1111/j.1523-1755.2004.00462.x

10.4049/jimmunol.173.12.7641

10.1016/j.clim.2010.03.008

10.1681/ASN.2006121348

10.4049/jimmunol.161.11.5880

10.4049/jimmunol.174.12.7600

10.1016/j.clim.2010.03.003

10.1038/nri2761

10.1073/pnas.0505539102

10.4049/jimmunol.174.7.4389

10.4049/jimmunol.180.1.361